Richardson Jonathan L, Stephens Sally, Chappell Lucy C, Campbell Helen, Amirthalingam Gayatri, O'Boyle Shennae, Bukasa Antoaneta, Knight Marian, Hodson Kenneth K
UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
School of Life Course Sciences, King's College London, London, UK.
Obstet Med. 2023 Mar;16(1):40-47. doi: 10.1177/1753495X221076713. Epub 2022 Feb 8.
COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection.
Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15 June 2021.
There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS ( = 493) and VIP ( = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common ( = 501, 55.2%), most women were vaccinated in their second or third trimester ( = 566, 62.3%), and were mainly vaccinated due to occupational infection risk ( = 577, 63.5%).
Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.
新冠病毒疫苗可预防疾病。孕妇接种疫苗有益，因为她们感染后出现不良孕产妇和新生儿结局的风险更高。
在英国两种新冠病毒疫苗获得监管批准后，利用三个现有的安全监测平台（英国产科监测系统、英国药品和医疗产品监管局药品不良反应监测系统和疫苗影响计划）开展了一项全国性的孕妇疫苗接种快速研究。本初步报告描述了截至2021年6月15日收集的数据。
在英国产科监测系统/英国药品和医疗产品监管局药品不良反应监测系统（n = 493）和疫苗影响计划（n = 478）监测系统中有971例新冠病毒疫苗接种报告，涉及908例单胎妊娠。辉瑞-BioNTech信使核糖核酸疫苗接种最为常见（n = 501，55.2%），大多数女性在孕中期或孕晚期接种（n = 566，62.3%），主要是由于职业感染风险而接种（n = 577，63.5%）。
产科结局数据将于2021年12月获得。然而，女性不应在等待更多安全数据出现时推迟接种疫苗。
